Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

scientific article published in April 2018

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis is …
instance of (P31):
meta-analysisQ815382
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMA.2018.2525
P932PMC publication ID5933331
P698PubMed publication ID29677301

P50authorPaul A GurbelQ89230591
Felicita AndreottiQ89285015
Mariusz KowalewskiQ92523001
Eliano P NavareseQ97551599
Jacek KubicaQ49506302
P2093author name stringPaolo Raggi
Jennifer G Robinson
Udaya Tantry
Kevin Bliden
Michalina Kolodziejczak
P2860cites workIntensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialQ24569666
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementQ27860537
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialQ28214393
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesQ28301815
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinQ29547752
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Q29547825
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)Q79792868
High-dose atorvastatin after stroke or transient ischemic attackQ80088259
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsQ29547887
A modified test for small-study effects in meta-analyses of controlled trials with binary endpointsQ29614902
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialQ29617817
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyQ29617822
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsQ29617910
Intensive versus moderate lipid lowering with statins after acute coronary syndromesQ29619716
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupQ29619842
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsQ29620696
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialQ29622926
Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse dataQ33688254
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.Q34043472
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Q34164324
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre raQ34189543
Efficacy and safety of alirocumab in reducing lipids and cardiovascular eventsQ34467233
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysisQ34473809
Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesQ34479098
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialQ34550538
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialQ34562602
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialQ34630074
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseQ35978349
Applicability of the Cochran Q test and the F test for statistical analysis of dichotomous data for dependant samplesQ36567897
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsQ38404786
Determining When to Add Nonstatin Therapy: A Quantitative ApproachQ39026191
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialQ39091664
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseQ40287836
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance studyQ42170155
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosisQ43638006
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trialQ44036282
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) studyQ44118533
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialQ44483019
Intensive lipid lowering with atorvastatin in patients with stable coronary diseaseQ45310626
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular riskQ52845873
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass graftsQ71966442
Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della SopravvivQ73749238
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trialQ79165142
P433issue15
P407language of work or nameEnglishQ1860
P921main subjectsystematic reviewQ1504425
P304page(s)1566-1579
P577publication date2018-04-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleAssociation Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis
P478volume319

Reverse relations

cites work (P2860)
Q64259306A Newly Integrated Model for Intestinal Cholesterol Absorption and Efflux Reappraises How Plant Sterol Intake Reduces Circulating Cholesterol Levels
Q92610593Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis
Q64062410Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis
Q57312936B vitamins for stroke prevention
Q99405143Bempedoic acid for the treatment of dyslipidemia
Q64927177Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem.
Q92223274Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Q92895582Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies
Q92890701Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
Q58738494Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty
Q89367205Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?
Q99616820Higher visit-to-visit total cholesterol variability is associated with lower cognitive function among middle-aged and elderly Chinese men
Q92158280Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Q57024998Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
Q64112851Life-Saving Medications: The Urgent Need for Guideline Adherence and Patient Acceptance
Q57118677Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients
Q57171783Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple
Q61603396Management of Blood Cholesterol
Q62489343Most Promising Therapies in Interventional Cardiology
Q93016817PCSK9 inhibitors: clinical evidence and implementation
Q58730393Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study
Q89553765Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population
Q92162898Preventive Pharmacotherapy for Cardiovascular Disease: A Modelling Study Considering Health Gain, Costs, and Cost-Effectiveness when Stratifying by Absolute Risk
Q55422159Reducing Low-Density Lipoprotein Cholesterol After Myocardial Infarction in Older Individuals, Levels Versus Change: Can Observational Studies Answer the Questions?
Q90690007Residual inflammatory risk after contemporary lipid lowering therapy
Q92308785Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy
Q61446050Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation
Q102060110The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Q92151548The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article)
Q93143695Total cholesterol and mortality from ischemic heart disease and overall cardiovascular disease in Korean adults
Q92649743Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
Q89944007Unripe Rubus coreanus Miquel Extract Containing Ellagic Acid Regulates AMPK, SREBP-2, HMGCR, and INSIG-1 Signaling and Cholesterol Metabolism In Vitro and In Vivo

Search more.